化脓性汗腺炎市场 - KOL的考察

本报告提供化脓性汗腺炎市场相关调查分析，对已上市的治疗方法和开发平台有的治疗方法的KOL的考察。

目录

摘要整理

治疗流程

调查目的

已上市/仿单标示外的治疗方法

• 抗肿瘤坏死因子TNF製剂
  • 修美乐（阿达木单抗；艾伯维）
  • Remicade（英夫利西单抗；Janssen/Merck & Co.）

管道疗法

• IL-17抑制剂
  • Cosentyx（苏金单抗；诺华）
  • Bimzelx（bimekizumab；UCB）
  • Izokibep（Acelyrin）
  • Sonelokimab（MoonLake 免疫疗法）
• IL-36抑制剂
  • Spevigo（spesolimab；勃林格殷格翰）
• JAK抑制剂
  • Povorcitinib（INCB54707；Incyte）
  • Jakafi/Jakavi（鲁索替尼；Incyte）
  • Rinvoq（upadacitinib；艾伯维）
• JAK/TYK 抑制剂
  • Brepocitinib（Priovant/辉瑞）
• 补体 C5a 抑制剂
  • Vilobelimab (InflaRx) 与 avacopan (Tavneos; Amgen/Vifor Fresenius)
• PDE4抑制剂
  • 奥司司特（UNION 疗法）
• 趋化因子 (CXCR1/2) 抑制剂
  • LY3041658（礼来）
• IL-1抑制剂
  • Lutikizumab（ABT-981；艾伯维）
• 其他作用机制
  • 重要考虑因素摘要

热射病管理的治疗动态

• 重要考虑因素摘要
  • 多项药物获批为 KOL 提供了更好的 HS 治疗选择：抗 IL17 疗法看来可能已站稳脚跟

HS市场前景与演变

• 重要考虑因素摘要
  • 疾病异质性和晚期疾病诊断是热射病治疗中的一些挑战

附录

KOL突发新闻

Expect significant and much needed expansion of therapy options in the HS treatment sector. Will Abbvie's Humira/biosimilar adalimumab maintain its first-line position? How do KOLs assess anti-IL17 drugs and why do they say that UCB's Bimzelx has an edge on Novartis' Cosentyx? Why are experts enthusiastic about oral JAK inhibitors, despite safety concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area:

• 21 Sep 2023 KOL Bulletin -- Views on top-line results from the Phase IIb/III trial of Acelyrin's izokibep in moderate-to-severe HS

Table of Contents

Executive summary (2)

Treatment algorithm (2)

Research objectives (1)

Marketed and off-label therapies (8)

• Anti-tumour necrosis factor TNF agents (8)
  • Humira (adalimumab; AbbVie) (8)
  • Remicade (infliximab; Janssen/Merck & Co.)

Pipeline therapies (47)

• IL-17 inhibitors (17)
  • Cosentyx (secukinumab; Novartis) (8)
  • Bimzelx (bimekizumab; UCB) (4)
  • Izokibep (Acelyrin) (3)
  • Sonelokimab (MoonLake Immunotherapeutics) (2)
• IL-36 inhibitors (1)
  • Spevigo (spesolimab; Boehringer Ingelheim) (1)
• JAK inhibitors (12)
  • Povorcitinib (INCB54707; Incyte) (6)
  • Jakafi/Jakavi (ruxolitinib; Incyte) (3)
  • Rinvoq (upadacitinib; AbbVie) (3)
• JAK/TYK inhibitor (1)
  • Brepocitinib (Priovant/Pfizer) (1)
• Complement C5a inhibitors (4)
  • Vilobelimab (InflaRx) and avacopan (Tavneos; Amgen/Vifor Fresenius) (4)
• PDE4 inhibitor (3)
  • Orismilast (UNION therapeutics) (3)
• Chemokine (CXCR1/2) inhibitor (3)
  • LY3041658 (Lilly) (3)
• IL-1 inhibitor (3)
  • Lutikizumab (ABT-981; AbbVie) (3)
• Other mechanisms of action (3)
  • Key insights summary (3)

Treatment dynamics for the management of HS

• Key insights summary
  • Multiple drug approvals will provide KOLs with better treatment options for HS: anti-IL17 therapies will become firmly established

Outlook and evolution of the HS market (1)

• Key insights summary (1)
  • Disease heterogeneity and late disease diagnosis comprise some of the challenges in the treatment of HS (1)

Appendix

• KOL details
  • KOLs from North America
  • KOLs from the Europe

KOL Bulletins (1)